OncoCyte
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of OncoCyte generated cash of -$23,325,000, which is more than the previous year. Cash used in financing activities reached the amount of $12,186,000 last year. Net change in cash is therefore -$12,071,000.
Cash Flow
| 2014 | -1.16M | 1.32M | 0 |
|---|---|---|---|
| 2015 | -4.22M | 315K | 11.65M |
| 2016 | -7.52M | -181K | 9.88M |
| 2017 | -13.38M | 843K | 9.96M |
| 2018 | -11.64M | -31K | 12.11M |
| 2019 | -19.71M | -12.41M | 47.86M |
| 2020 | -25.98M | -11.74M | 22.79M |
| 2021 | -35.94M | -13.96M | 78.36M |
| 2022 | -45.56M | -4.34M | 35.80M |
| 2023 | -23.32M | -932K | 12.18M |
OCX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 23.20M | 37.30M | 8.84M | 23.77M | 8.03M | 7.6M | 10.17M | 7.99M | 257K | 101K |
Operating activities | ||||||||||
Net income | -27.78M | -72.90M | -64.09M | -29.93M | -22.42M | -15.75M | -19.37M | -11.16M | -8.73M | -4.98M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.68M | 5.22M | 4.20M | 1.89M | 351K | 559K | 580K | 387K | 283K | 281K |
Stock-based compensation expense | 6.57M | 10.04M | 6.84M | 5.06M | 2.99M | 0 | 1.63M | 922K | 1.81M | 318K |
| Deferred income tax benefit | 6.57M | 10.04M | 6.84M | 5.06M | 2.99M | 0 | 1.63M | 922K | 1.81M | 318K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 109K | -575K | -1.22M | -182K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -4.75M | 297K | -1.34M | 854K | 741K | 1.00M | -48K | 229K | 1.04M | 291K |
Cash generated by operating activities | -23.32M | -45.56M | -35.94M | -25.98M | -19.71M | -11.64M | -13.38M | -7.52M | -4.22M | -1.16M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -4M | -11.24M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -281K | -4.34M | -2.24M | -1.22M | -918K | -31K | -91K | -106K | -500K | -9K |
Acquisitions Net | 0 | 0 | -11.71M | -10.51M | -11.24M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -932K | -4.34M | -13.96M | -11.74M | -12.41M | -31K | 843K | -181K | 315K | 1.32M |
Financing activities | ||||||||||
Common Stock Issued | 13.84M | 32.84M | 80.52M | 20.80M | 48.85M | 0 | 8.38M | 10.55M | 11.64M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -1.11M | 0 | -239K | -14K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -117K | -1.42M | -1.53M | -446K | 1.36M | -1.18M | 1.58M | -114K | 0 | 0 |
Cash used in financing activities | 12.18M | 35.80M | 78.36M | 22.79M | 47.86M | 12.11M | 9.96M | 9.88M | 11.65M | 0 |
Net Change In Cash | -12.07M | -14.10M | 28.46M | -14.92M | 15.73M | 434K | -2.57M | 2.17M | 7.73M | 156K |
Cash at end of period | 11.13M | 23.20M | 37.30M | 8.84M | 23.77M | 8.03M | 7.6M | 10.17M | 7.99M | 257K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |